Core Insights - On November 12, BeiGene's stock rose by 5.62%, with a trading volume of 1.793 billion yuan [1] - As of November 12, BeiGene's total margin trading balance reached 1.332 billion yuan, indicating a high level of trading activity [1] Financing Summary - On November 12, BeiGene had a financing buy-in amount of 201 million yuan, while the financing repayment was 231 million yuan, resulting in a net financing outflow of 30.15 million yuan [1] - The current financing balance of 1.312 billion yuan accounts for 3.88% of the circulating market value, which is above the 90th percentile level over the past year [1] Securities Lending Summary - On November 12, BeiGene repaid 1,200 shares in securities lending and sold 2,015 shares, amounting to a selling value of 591,600 yuan based on the closing price [1] - The remaining securities lending balance is 66,600 shares, with a total value of 19.56 million yuan, also exceeding the 90th percentile level over the past year [1] Company Overview - BeiGene, established on October 28, 2010, and listed on December 15, 2021, is located in the Zhongguancun Life Science Park, Beijing [1] - The company's main business involves the research, development, production, and commercialization of innovative drugs, with 99.10% of revenue coming from drug sales and 0.90% from collaboration arrangements [1] Shareholder Information - As of September 30, the number of BeiGene shareholders increased by 55.33% to 36,200, while the average circulating shares per person decreased by 35.79% to 3,195 shares [2] - For the period from January to September 2025, BeiGene reported a revenue of 27.595 billion yuan, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion yuan, up 130.88% year-on-year [2] Institutional Holdings - As of September 30, among the top ten circulating shareholders, China Europe Medical Health Mixed A ranked fourth with 4.6788 million shares, a decrease of 146,600 shares from the previous period [2] - Hong Kong Central Clearing Limited entered as a new shareholder, holding 3.1565 million shares, while other notable changes included a significant reduction in holdings by several funds [2]

Core Viewpoint - The company plans to increase funding for its drug clinical trial research project using remaining raised funds and extend the project's implementation period until December 31, 2026 [17][26]. Group 1: Financial Data - The adjusted operating profit for the first three quarters of 2025 is 5.543 billion yuan, compared to 52 million yuan in the same period last year [6]. - The adjusted net profit for the first three quarters of 2025 is 4.729 billion yuan, compared to a net loss of 474 million yuan in the same period last year [6]. - The net cash flow from operating activities, after deducting capital expenditures, is 3.200 billion yuan, compared to -4.797 billion yuan in the same period last year [6]. Group 2: Fundraising and Investment - The company raised a total of 2.216 billion yuan from its initial public offering, with a net amount of 2.163 billion yuan after deducting issuance costs [19]. - The company intends to use 163.155 million yuan of the remaining raised funds to increase investment in the drug clinical trial research project [18][22]. - The project includes various stages of drug development, such as preclinical and clinical research, and aims to enhance the company's innovative drug development capabilities [21][24]. Group 3: Project Implementation and Timeline - The implementation period for the drug clinical trial research project will be extended to December 31, 2026, to accommodate the increased funding and project needs [26]. - The company emphasizes the necessity and feasibility of increasing funding for the project to maintain its competitive edge in innovative drug development [24][25]. - The project will be closely monitored to ensure efficient use of funds and timely completion [27].

Major Events - Hong Kong Stock Exchange (00388) plans to make a strategic investment in Xunqing Settlement Holdings Limited [1] - Lai Kai Pharmaceutical-B (02105) signs an exclusive licensing agreement with Qilu Pharmaceutical for LAE 002 (AFURESERTIB) in China [1] - TECHSTARACQ-Z (07855) is expected to inherit the company Tuda Tong's listing on the main board of the Stock Exchange on December 10 [1] - Superstar Legend (06683) intends to establish a joint venture with Yushu Technology to develop consumer-grade IP robots and IP derivative products [1] - Beijing Enterprises Holdings (00392) plans to acquire 100% equity of Beijing Beiran Special Equipment Inspection and Testing Co., Ltd. for 54.6 million yuan [1] - CSPC Pharmaceutical Group (01093) has its application for the marketing of Pertuzumab Injection accepted by the National Medical Products Administration [1] - Rongli Construction (09639) plans to collaborate with CATL to develop efficient energy storage systems and solutions [1] Operating Performance - BeiGene (06160) reports a net profit attributable to shareholders of 1.139 billion yuan for the first three quarters, turning from loss to profit year-on-year [1] - Tencent Music-SW (01698) reports a net profit attributable to equity holders of 2.15 billion yuan in the third quarter, a year-on-year increase of 36.0% [1] - Zhou Li Fu (06168) sees a 32% year-on-year increase in e-commerce revenue for the first ten months, with net profit rising 71% year-on-year [1] - China Resources Land (01109) reports a cumulative contract sales amount of approximately 169.6 billion yuan for the first ten months, a year-on-year decrease of 16.6% [1]

Market Overview - Hong Kong stocks showed a positive trend, closing up 0.85% as bulls took control, indicating a lack of negative news is perceived as positive [1] - The U.S. House of Representatives is expected to vote on a compromise plan to end the longest government shutdown in U.S. history, which could restore funding to government agencies [1] - The ADP private sector employment report for October showed a decrease of 45,000 jobs, the largest drop in two and a half years, suggesting a cooling labor market and increasing expectations for a Fed rate cut in December [1] Sector Performance - The banking sector saw a rebound with major banks like Agricultural Bank of China reaching new highs, driven by long-term investments from insurance funds and public funds [1] - Consumer sectors are gaining traction, with companies like "Hushang Auntie" seeing a significant increase of nearly 29%, indicating a recovery in consumer sentiment [2] - Retail sales in Hong Kong are projected to rise by 4% year-on-year in October, benefiting retail rental stocks [3] Company Highlights - Baijie Shenzhou reported a 44.2% increase in total revenue for the first three quarters, driven by sales growth of its self-developed products [3] - Xiaomi announced a significant sales figure of over 29 billion yuan during the Double 11 shopping festival, indicating strong consumer demand [4] - The Ximangdu iron ore project, with reserves exceeding 4.4 billion tons, has commenced production, potentially altering the global iron ore supply landscape and benefiting companies like Maanshan Iron & Steel [5] Industry Developments - The Chinese commercial aerospace sector is set to advance with the upcoming maiden flight of the reusable rocket "Zhuque-3," which aims to reduce launch costs significantly [6] - The sportswear manufacturing sector is expected to see a recovery in demand, with Shenzhou International projecting a 15.3% increase in revenue for the first half of 2025 [7] - The company has expanded its overseas production capacity, with 53% of its garment output coming from international facilities, indicating a strategic shift towards globalization [8]

Group 1: Company Performance - BeiGene reported a revenue of 10.077 billion yuan for Q3 2025, representing a year-on-year increase of 41.1%, with a net profit of 689 million yuan [1] - For the first three quarters of 2025, BeiGene's revenue reached 27.595 billion yuan, up 44.2% year-on-year, with a net profit of 1.139 billion yuan [1] Group 2: Share Buyback and Capital Reduction - Century Huatong announced a plan to repurchase shares worth 500 million to 1 billion yuan, which will be fully canceled to reduce the registered capital, with a maximum price of 28.77 yuan per share [2] Group 3: Shareholding Changes - Shannon Chip announced that the Wuxi High-tech Zone New Energy Industry Development Fund reduced its holdings by 549,200 shares, decreasing its stake from 5.12% to 4.999985% [3] - Founder Electric reported that shareholder Zhang Min reduced his holdings by a total of 1.6324 million shares on November 10 and 12, 2025, representing 0.33% of the total share capital, leaving him with 24.7936 million shares, or 5% of the total [4] Group 4: Legal Issues - North Medical's chairman Xu Xiren was arrested for suspected criminal activity, with the board's operations remaining normal and no change in control [5] Group 5: Corporate Governance Changes - Jiuzhou Pharmaceutical elected Hua Lirong as the executive director and legal representative, following the transfer of significant equity stakes from her father [6] Group 6: Strategic Partnerships - Haibo Sichuang signed a strategic cooperation agreement with CATL, committing to procure a total of no less than 200 GWh of electricity from 2026 to 2028 [7][8] Group 7: Regulatory Approvals - Yiling Pharmaceutical's wholly-owned subsidiary received approval for the listing application of the raw material drug Memantine Hydrochloride, aimed at treating moderate to severe Alzheimer's disease [9]

Core Viewpoint - BeiGene has announced an increase in funding for its drug clinical trial research project, utilizing remaining over-raised funds of 163.15 million yuan, extending the project deadline to December 31, 2026 [1][3]. Fund Utilization Overview - BeiGene completed its A-share IPO in December 2021, raising a total of 22.15964 billion yuan, with a net amount of 21.63015 billion yuan after deducting issuance costs. As of June 30, 2025, the company has utilized 19.65094 billion yuan of the raised funds [2]. - The specific allocation of the raised funds includes various projects, with the drug clinical trial research project being a significant focus [2]. Increased Investment Details - The additional funding will be directed entirely towards "preclinical research costs" within the drug clinical trial research project, which encompasses various stages of drug development [3]. - The total planned investment for the project will increase from 13.24594 billion yuan to 13.40909 billion yuan, while the overall project investment remains unchanged at 15.2807 billion yuan [3]. R&D Strategy and Importance - BeiGene emphasizes that continuous investment in R&D is crucial for maintaining its technological advantage as a leading global oncology innovation company. The company has established a comprehensive R&D system covering various fields, including molecular targeted drugs and immuno-oncology therapies [4]. - The new funding will focus on preclinical research, including expenses for reagents, equipment, facility rentals, and personnel, enhancing the company's independent R&D platform and system [4].

Core Insights - BeiGene reported a revenue of RMB 27.595 billion for the first three quarters of 2025, representing a year-on-year growth of 44.2% [1] - The net profit attributable to shareholders of the listed company was RMB 1.139 billion, marking a turnaround from loss to profit compared to the previous year [1] - Basic earnings per share stood at RMB 0.81 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司關於使用超募資 金對募投項目增加募集資金投入並延長項目實施期限的公告》以及《中國國際金融 股份有限公司、高盛（中國）證券有限責任公司關於百濟神州有限公司使用超募資 金對募投項目增加募集資金投入並延長項目實施期限的核查意見》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年11月12日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事 王曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司2025年第三季度 報告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年11月12日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事 王曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、Corazon (Corse ...

Core Viewpoint - The Medical Health R Index (480016) closed at 7616.59 points, up 0.5%, with a trading volume of 25.943 billion yuan and a turnover rate of 0.88% on November 12. The index saw 27 stocks rise, led by BeiGene with a 5.62% increase, while 21 stocks fell, with Tigermed leading the decline at 1.68% [1]. Group 1: Index Performance - The Medical Health R Index reported a net inflow of 537 million yuan from main funds, while retail and speculative funds experienced net outflows of 264 million yuan and 273 million yuan, respectively [1]. - The top ten constituent stocks of the index include WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 13.66%, 11.00%, and 7.57% [1]. Group 2: Stock Details - BeiGene (688235) had the highest increase at 5.62%, closing at 293.62 yuan with a market capitalization of 452.37 billion yuan [1]. - Hengrui Medicine (600276) saw a 1.70% increase, closing at 62.10 yuan with a market capitalization of 412.17 billion yuan [1]. - WuXi AppTec (603259) experienced a slight decrease of 0.16%, closing at 92.35 yuan with a market capitalization of 275.55 billion yuan [1]. Group 3: Fund Flow Analysis - Hengrui Medicine had a main fund net inflow of 2.74 million yuan, while speculative funds saw a net outflow of 60.98 million yuan [2]. - BeiGene also experienced a main fund net inflow of 1.81 million yuan, with speculative funds facing a net outflow of 172 million yuan [2]. - The overall fund flow indicates a mixed sentiment among investors, with main funds showing some interest while retail and speculative funds are withdrawing [2].